Aditx acquires Ignite Proteomics, LLC

Aditxt, Inc. has acquired Ignite Proteomics, LLC in a $36 million transaction aimed at enhancing the precision of therapy selection in cancer care. The acquisition underscores Aditxt's strategy to advance healthcare innovations, particularly in precision oncology, where optimizing treatment options is crucial for patients with metastatic cancer.

Ignite Proteomics, a commercial-stage company, offers a functional proteomics platform that identifies cancer therapy responses beyond conventional genomic testing. The acquired company's proprietary technology addresses a significant challenge in cancer care by helping physicians select the most effective therapies. Ignite plans a 2026 rollout of its program focusing on metastatic cancer patients, which could impact over 600,000 individuals in the U.S. alone. This strategic acquisition aligns with Aditxt's mission to accelerate impactful health solutions.

Aditxt's CEO, Amro Albanna, emphasized the acquisition's alignment with the company's broader strategy of integrating novel healthcare technologies. With millions of cancer patients facing limited treatment options, the need for precise therapeutic interventions has intensified. Ignite's platform promises to enhance treatment decision-making by focusing on whether a patient’s tumor expresses necessary biological targets for advanced therapeutics. The acquisition dovetails with the expanding targeted therapy sector, including antibody drug conjugates (ADCs), where accurate tumor profiling is vital.

The global cancer profiling market is projected at approximately $14 billion, with Ignite identifying a $3 billion serviceable segment for patients potentially benefiting from ADC therapies. Ignite differentiates itself with a CLIA-certified laboratory and a Medicare Proprietary Laboratory Analyses (PLA) reimbursement pathway, pricing tests at around $2,200 each. This financial and operational infrastructure positions Ignite ahead of many early-stage diagnostics companies. The platform supports both therapy selection and ongoing monitoring, crucial as precision therapies evolve.

Looking forward, Ignite aims to integrate its RPPA platform within oncology practices and collaborate with Molecular Tumor Boards, focusing on patient populations with limited conventional biomarker options. By leveraging licensed intellectual property and existing reimbursement pathways, Ignite is poised to influence treatment paradigms where protein-level tumor evaluations guide therapeutic decisions. The completion of this acquisition marks a critical step in Aditxt's efforts to expand its footprint in oncology through innovative technologies.